Sagimet Biosciences (STU:0O2) Asset Impairment Charge: €0.00 Mil (TTM As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.70
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Asset Impairment Charge?

Sagimet Biosciences STU:0O2 +9.12% 10 Asset Impairment Charge is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Sagimet Biosciences's Asset Impairment Charge for the three months ended in Mar. 2026 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Sagimet Biosciences Asset Impairment Charge Related Terms

Sagimet Biosciences Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Asset Impairment Charge Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.20

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

What does a Asset Impairment Charge of €0.00 Mil mean?
Sagimet Biosciences (STU:0O2) has a Asset Impairment Charge of €0.00 Mil as of Mar. 2026.
Is Sagimet Biosciences' Asset Impairment Charge too high?
Sagimet Biosciences' current Asset Impairment Charge is €0.00 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Asset Impairment Charge compare to EDIT and AUTL?
Sagimet Biosciences' Asset Impairment Charge of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Sagimet Biosciences's current Asset Impairment Charge is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Asset Impairment Charge of €0.00 Mil. The current Asset Impairment Charge is €0.00 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Asset Impairment Charge is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.70
Price